Featured Research

from universities, journals, and other organizations

Engineered Protein-like Molecule Protects Cells Against HIV Infection

Date:
August 18, 2009
Source:
University of Wisconsin-Madison
Summary:
With the help of the human immunodeficiency virus (HIV) and molecular engineering, researchers have designed synthetic protein-like mimics convincing enough to interrupt unwanted biological conversations between cells.

With the help of the human immunodeficiency virus (HIV) and molecular engineering, researchers have designed synthetic protein-like mimics convincing enough to interrupt unwanted biological conversations between cells.

Interactions between proteins are fundamental to many biological processes, including some less-than-desirable ones like infections and tumor growth. For example, HIV and several other human viruses — including influenza, Ebola and the severe acute respiratory syndrome (SARS) virus — rely on interactions both among their own proteins and with host cell proteins to infect the cells.

"There's a lot of information transfer that occurs when proteins come together, and one would often like to block that information flow," says Samuel Gellman, a chemistry professor at the University of Wisconsin-Madison.

In a fundamental study of how to control protein shape, Gellman's UW-Madison research team, including former postdoctoral fellow W. Seth Horne, now at the University of Pittsburgh, and graduate student Lisa Johnson, created a set of peptide-like molecules that successfully blocked HIV infection of human cells in laboratory experiments.

By interacting with a piece of a crucial HIV protein called gp41, the synthetic molecules physically prevent the virus from infecting host cells.

The idea shows promise as a new avenue for targeting other unwanted protein interactions as well, Gellman says. The work, performed with a group led by John Moore and Min Lu at the Weill Medical College of Cornell University, is described in a paper appearing online the week of Aug. 17 in the Proceedings of the National Academy of Sciences.

Past attempts to prevent infection by selectively interfering with these interactions have had limited success, he says. Most drugs are small molecules and are not very effective at blocking most protein-protein interactions, which involve large molecular surfaces. Short snippets of proteins, or peptides, can be more effective than small molecules but are easily broken down by enzymes in the body and so require large and frequent doses that are difficult for patients to manage.

The new synthetic approach avoids these pitfalls by creating peptide-like molecules with a modified structure that degrading enzymes have trouble recognizing.

"We want to find an alternate language, an alternate way to express the information that the proteins express so that we can interfere with a conversation that one protein is having with another," Gellman explains.

Like engineers adjusting molecular blueprints, Gellman and his colleagues made structural tweaks to the backbones of their synthetic molecules to improve stability while retaining the three-dimensional shape necessary to recognize and interact with the HIV gp41 protein. The resulting molecules — dubbed "foldamers" — are hybrids of natural and unnatural amino acid building blocks, a combination that allows the scientists to control shape, structure and stability with much greater precision than is currently possible with natural amino acids alone.

In addition to adopting a shape that can interrupt the protein-protein dialogue, the novel foldamer has the additional advantage of being highly resistant to degradation by naturally occurring enzymes, which are stymied by the foldamer's unusual structure. This means the molecule can remain effective for a longer time and at lower doses.

Several of the synthetic foldamers showed potent antiviral activity against HIV when applied to cultured human cell lines in a dish. Although it is not clear that the foldamers themselves could ever be used as anti-HIV drugs, Gellman emphasizes, the results show that this type of approach has great potential to lead to new ways to think about designing molecules for antiviral therapies and other biomedical applications.

"You don't have to limit yourself to the building blocks that nature uses," Gellman says. "There's a huge potential here because the strategy we use is different from what the pharmaceutical and biotech industries now employ."

The study was supported by grants from the National Institutes of Health.


Story Source:

The above story is based on materials provided by University of Wisconsin-Madison. Note: Materials may be edited for content and length.


Cite This Page:

University of Wisconsin-Madison. "Engineered Protein-like Molecule Protects Cells Against HIV Infection." ScienceDaily. ScienceDaily, 18 August 2009. <www.sciencedaily.com/releases/2009/08/090817184441.htm>.
University of Wisconsin-Madison. (2009, August 18). Engineered Protein-like Molecule Protects Cells Against HIV Infection. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2009/08/090817184441.htm
University of Wisconsin-Madison. "Engineered Protein-like Molecule Protects Cells Against HIV Infection." ScienceDaily. www.sciencedaily.com/releases/2009/08/090817184441.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins